Abstract
Aims
Inflammatory bowel disease (IBD) management entails long‐term medication therapy. Worse disease outcomes and reduced quality of life might arise from poor medication adherence (MA). This study is the first to investigate patients with IBD's adherence across Aotearoa New Zealand and its relationship with disease outcomes.
Methods
Dispensing claims data (Pharmaceutical Collection) were used to calculate (3‐ and 5‐year) adherence, using daily polypharmacy possession ratio. Using hospitalization data (National Minimum Dataset), the relationship between adherence and the numbers of hospitalizations and corticosteroid dispensings was investigated.
Results
In total, 4654 patients (53% female; 55% Crohn's disease [CD], 45% ulcerative colitis [UC]; median age‐at‐first‐dispensing, 43 years) and 3148 patients (54% female; 55% CD, 44% UC; median age‐at‐first‐dispensing, 44 years) were in the 3‐ and 5‐year cohorts, respectively. The 3‐ and 5‐year cohorts had mean 4.6 and 4.2 IBD‐related hospitalizations and 6.9 and 9.2 corticosteroid dispensings, respectively. Average adherence estimates were 77.4% (95% confidence interval: 76.9–78.0%) and 74.9% (95% confidence interval: 74.1–75.6%; 3 and 5 years), while 54% and 51% of patients, respectively, had good adherence (MA ≥ 80%). There was no correlation between adherence and the numbers of hospitalizations (Pearson's R = −.0007; P = .65 and R = −.04; P = .02 [3 and 5 years]) and corticosteroid dispensings (R = .08; P = <.0001 and R = .08; P = <.0001, respectively).
Conclusion
MA of Aotearoa New Zealand patients with IBD is moderately high but just over half of patients meet the adherent threshold. There was no correlation between adherence and hospitalizations or corticosteroid dispensings; hence, research into longitudinal adherence patterns and associated factors is needed.